SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients

We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1 + myeloid cells in demyelinating diseases. We performed flow cytometry-based measurements of SIGLEC1 expression on monocytes in 86...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2021-05, Vol.11 (1), p.10299-10299, Article 10299
Main Authors: Ostendorf, Lennard, Dittert, Philipp, Biesen, Robert, Duchow, Ankelien, Stiglbauer, Victoria, Ruprecht, Klemens, Bellmann-Strobl, Judith, Seelow, Dominik, Stenzel, Werner, Niesner, Raluca A., Hauser, Anja E., Paul, Friedemann, Radbruch, Helena
Format: Article
Language:English
Subjects:
631/250/371
692/617/375
Autoimmune diseases
Central nervous system
Demyelinating diseases
Demyelination
Flow cytometry
Humanities and Social Sciences
Immunomodulation
Inflammation
Interferon
Lesions
Monocytes
multidisciplinary
Multiple sclerosis
Myeloid cells
Neurological diseases
Neuromyelitis
Science
Science (multidisciplinary)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1 + myeloid cells in demyelinating diseases. We performed flow cytometry-based measurements of SIGLEC1 expression on monocytes in 86 MS patients, 41 NMOSD patients and 31 healthy controls. Additionally, we histologically evaluated the presence of SIGLEC1 + myeloid cells in acute and chronic MS brain lesions as well as other neurological diseases. We found elevated SIGLEC1 expression in 16/86 (18.6%) MS patients and 4/41 (9.8%) NMOSD patients. Almost all MS patients with high SIGLEC1 levels received exogenous interferon beta as an immunomodulatory treatment and only a small fraction of MS patients without interferon treatment had increased SIGLEC1 expression. In our cohort, SIGLEC1 expression on monocytes was—apart from those patients receiving interferon treatment—not significantly increased in patients with MS and NMOSD, nor were levels associated with more severe disease. SIGLEC1 + myeloid cells were abundantly present in active MS lesions as well as in a range of acute infectious and malignant diseases of the central nervous system, but not chronic MS lesions. The presence of SIGLEC1 + myeloid cells in brain lesions could be used to investigate the activity in an inflammatory CNS lesion.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-89786-0